TIDMDXRX

RNS Number : 2604N

Diaceutics PLC

21 September 2023

Diaceutics PLC - Directorate Changes

Graham Paterson appointed as an independent Non-Executive Director

Charles Hindson retiring as a Non-Executive Director

Belfast and London, 21 September 2023 - Diaceutics PLC (AIM: DXRX) , a leading technology and solutions provider to the pharmaceutical industry, today announces the appointment of Graham Paterson as an independent Non-Executive Director of Diaceutics PLC effective 1 October 2023. The Company also announces the retirement of Charles Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October 2023.

Graham Paterson is a highly experienced business leader and Non-Executive Director. He is currently a Non-Executive Director of Invesco Perpetual UK Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income and Growth 4 VCT plc. He has held senior executive roles in a number of companies including TopQ Software Ltd and SL Capital Partners.

Graham Paterson is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland and holds an Honours degree in Economics and Management from the University of St. Andrews. On appointment, Graham Paterson will become Chair of the Audit and Remuneration Committees of Diaceutics PLC.

Deborah Davis, Diaceutics' Non-Executive Chair, commented: "I would like to thank Charles for his hard work, dedication and much valued counsel during the past four years and wish him well in his future endeavours.

I warmly welcome Graham to the board of Diaceutics, his extensive leadership and board experience will contribute significantly to our work and support our growth as we become the primary commercialisation partner for pharma and biotech companies launching precision medicines."

Information required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

The following information is disclosed in relation to Graham Douglas Paterson, aged 52:

 
 Current Directorships             Past Directorships (previous 
                                    5 years) 
 Baillie Gifford US Growth         The IDco Ltd 
  Trust Plc 
                                    Octopus VCT 4 Plc 
  Invesco Perpetual UK Smaller 
  Companies Investment Trust        Berry Starquest Limited 
  Plc 
 
  Mobeus Income and Growth 
  4 VCT Plc 
 
  Datactics Ltd 
 
  Substantive Research Ltd 
 
  The Wemyss Development Company 
  Ltd 
 
  GDP 1 Ltd 
                                  -----------------------------

Graham Paterson does not hold any ordinary shares or share options in the Company.

Save for the information disclosed above, there is no other information to be disclosed under Schedule 2(g) of the AIM Rules.

Enquiries:

 
Diaceutics PLC                                   Tel: +44 (0)28 9040 6500 
Peter Keeling, Chief Executive Officer   investorrelations@diaceutics.com 
 Ryan Keeling, Chief Innovation Officer 
 Nick Roberts, Chief Financial Officer 
 
 
Stifel Nicolaus Europe Limited (Nomad            Tel: +44 (0)20 7710 7600 
 & Broker) 
Ben Maddison 
Nick Harland 
 Kate Hanshaw 
 
 
Alma PR                                          Tel: +44 (0)20 3405 0205 
Caroline Forde                                    diaceutics@almapr.co.uk 
Matthew Young 
Kinvara Verdon

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostic Network(R).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOALBMJTMTJTBJJ

(END) Dow Jones Newswires

September 21, 2023 09:37 ET (13:37 GMT)

Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Diaceutics Charts.
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Diaceutics Charts.